Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | FGR | P09769 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26109541 | 1.00 | KRAS (0.34) | KRASBTKSYKAURKAFGR | |
| SCHEMBL30064070 | 1.00 | KRAS (0.34) | KRASBTKSYKAURKAFGR | |
| SCHEMBL23816067 | 0.91 | KRAS (0.33) | KRASBTKHDAC4 | |
| SCHEMBL30063513 | 0.91 | KRAS (0.33) | KRASBTKHDAC4 | |
| SCHEMBL26110984 | 0.91 | KRAS (0.33) | KRASBTKHDAC4 | |
| SCHEMBL23816135 | 0.80 | BTK (0.33) | BTKSYKHDAC4 | |
| SCHEMBL30063454 | 0.80 | BTK (0.35) | BTKAURKAFGRCYP2C9SRC | |
| SCHEMBL26117243 | 0.80 | BTK (0.35) | BTKAURKAFGRCYP2C9SRC | |
| SCHEMBL26117250 | 0.80 | BTK (0.35) | BTKAURKAFGRCYP2C9SRC | |
| SCHEMBL26114422 | 0.80 | HDAC4 (0.35) | KRASBTKHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-115335376-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitor with E3 ligase ligand and methods of use thereof | 百济神州有限公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | KRAS 1457/4885BTK 1/4885SYK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.